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Purpose: Maximum dose to the left anterior descending artery (LADmax) is an important physical
constraint to reduce the risk of cardiovascular toxicity. We generated a simple algorithm to guide
the positioning of the tangent ﬁelds to reliably maintain LADmax <10 Gy.
Methods and materials: Dosimetric plans from 146 consecutive women treated prone to the
left breast enrolled in prospective protocols of accelerated whole breast radiation therapy,
with a concomitant daily boost to the tumor bed (40.5 Gy/15 fraction to the whole breast and 48 Gy
to the tumor bed), provided the training set for algorithm development. Scatter plots and correlation
coefﬁcients were used to describe the bivariate relationships between LADmax and several pa-
rameters: distance from the tumor cavity to the tangent ﬁeld edge, cavity size, breast separation,
ﬁeld size, and distance from the tangent ﬁeld. A logistic sigmoid curve was used to model the
relationship of LADmax and the distance from the tangent ﬁeld. Furthermore, we tested this
prediction model on a validation data set of 53 consecutive similar patients.
Results: A lack of linear relationships between LADmax and distance from cavity to LAD
(0.47), cavity size (0.18), breast separation (0.02), or ﬁeld size (0.28) was observed. In
contrast, distance from the tangent ﬁeld was highly negatively correlated to LADmax (-0.84)
and was used in the models to predict LADmax. From a logistic sigmoid model we selected a
cut-point of 2.46 mm (95% conﬁdence interval, 2.19-2.74 mm) greater than which LADmax is
<10 Gy (95% conﬁdence interval, 9.30-10.72 Gy) and LADmean is <3.3 Gy.Sources of support: This work was supported in part by National Cancer Institute CCSG P30 CA016087 (J.D.G.).
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contoured LAD is likely to assure LADmax is <10 Gy and LADmean is <3.3 Gy in patients
treated with prone accelerated breast radiation therapy.
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Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The fundamental law of radiobiology proposed by
Bergonié and Tribondeau in 1906 postulated that highly
differentiated organs with a low mitotic index are radio-
resistant and therefore described the heart as the quintes-
sential radioresistant organ.1 However, multiple studies
from the treatment of Hodgkin disease, breast cancer, and
peptic ulcer disease have all refuted this claim and
demonstrated a signiﬁcant cardiac risk when portions of the
heart are irradiated.2-4 Radiation-induced cardiotoxicity
remains an ongoing area of concern, particularly in curable
early-stage breast cancer, where the survival advantage
conveyed by radiation therapy is mitigated by a signiﬁcant
increase in mortality from heart disease that is sustained 15
years following radiation therapy to the left breast, as
demonstrated in a large Surveillance, Epidemiology, and
End Results registry study.2,5,6 Because of its proximity to
the anterior chest wall, the left anterior descending coronary
artery (LAD) is often signiﬁcantly exposed to breast radia-
tion and is a major cause of this complication.7 Generally,
the mean LAD dose (LADmean) is monitored as a surrogate
predictor of cardiotoxicity.8,9 However, a recent study of
cardiac perfusion imaging with stress single photon emis-
sion computed tomography (CT) scans before and after
comprehensive nodal irradiation in 32 women with left-
sided breast cancer failed to detect a correlation between
clinically signiﬁcant defects and heart or LADmean dose.10
The maximum LAD dose (LADmax) may be more
clinically relevant, considering the classical pathophysi-
ology of coronary heart disease, because occlusion of only 1
section of the LAD can result in symptomatic heart disease.
Scant preclinical evidence on radiation dose and fraction-
ation response of the LAD is available. A maximum single
dose to the LAD>10 Gy has been shown to cause coronary
artery sclerosis in a rodent preclinical model.11 In the clin-
ical setting of fractionated radiation therapy, reducing
LADmax to <10 Gy is likely to be an adequate precaution.
In the prone position, we routinely contour the LAD as
an avoidance structure and design tangent ﬁelds to
exclude the LAD from the primary beam. However, when
developing radiation portals, one cannot reliably predict
the exact dose structures outside of the primary beam will
receive, because the dose may reﬂect multiple variables
such as the breast size and shape as well as the tumor
cavity size and location. Once dosimetric planning isoptimized with intensity modulation or ﬁeld-in-ﬁeld
design and the dose is calculated, even minor adjust-
ments are time and labor intensive. We hypothesized that
deﬁning the closest distance of the LAD to the tangent
ﬁelds could offer a reliable prediction of the LADmax,
particularly with a prone setup, which is characterized by
minimal intrafraction displacement of the chest wall and
highly reproducible intrafraction positioning.12,13
We used a dosimetry database of 146 consecutive left
breast cancer patients as a training set to determine the
minimum LAD distance from the edge of the tangent
ﬁelds required to consistently assure a LADmax <10 Gy.
We then prospectively collected the plans of 53 consec-
utive left breast cancer patients to create a validation set to
test the validity of our model.Methods and materials
Dosimetric plans from consecutive, early breast cancer
patients enrolled in 2 institutional review board-
eapproved prospective protocols (05-181 and 12-01299),
who had undergone segmental mastectomy and were
treated with standard tangent ﬁelds alone were reviewed.
Patients in 05-181 were treated to the whole breast to a
dose of 2.7 Gy with an additional daily boost to the
postsurgical cavity of 0.5 Gy a day over 15 fractions (48
Gy total). Women in 12-01299 were treated to the whole
breast to a dose of 2.7 Gy and randomized to an additional
boost delivered to the postsurgical cavity of 0.5 Gy a day
(daily arm, 48 Gy total) or 2 Gy on the Fridays before the
weekend break (weekly arm, 46.5 Gy total).
Women treated to the left breast in the prone position
were included in this training set and their LAD was
contoured on noncontrast simulation CT scans. This se-
ries of 146 consecutive patients enabled adequate repre-
sentation of anatomic variability and different
postsurgical cavity size and location. Variables measured
included: distance from the tumor cavity to the LAD
deﬁned as the shortest distance from the contoured tumor
cavity to the LAD in the beams-eye view; tumor cavity
volume; breast separation measured from the anterior
edge of the latissimus dorsi to the medial sternum; and
width of the left posterior oblique (LPO) tangent ﬁeld in
the anteroposterior (AP) direction. The maximum point
dose to the LAD was identiﬁed for each individual
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the LADmax was measured using the Eclipse (Varian
Medical Systems, Palo Alto, CA) treatment planning
software (Fig 1). This was determined by ﬁrst identifying
the maximum point dose to the LAD on the simulation
CT scan, and then measuring the perpendicular distance
from this point to the ﬁeld edge on the same CT slice.
Information from the plans of 53 consecutive left-sided
breast cancer patients (consented to protocol 12-01299)
were then prospectively acquired to generate a validation
set to test the model obtained from the training set, in an
independent cohort. Patients were included from both the
daily and weekly boost arm. LADmax dose values were
multiplied by 1.03225 (48 Gy/46.5 Gy) in the weekly
boost arm to normalize the total dose delivered to 48 Gy.
Statistical methods
We ﬁrst provide a summary of the characteristics for
the 146 patients included in the training set. For these 146
patients, scatter plots and correlation coefﬁcients were
used to describe the bivariate relationships between the
LADmax and distance from boost cavity to LAD, cavity
size, breast separation, ﬁeld size in the AP direction of the
LPO ﬁeld, and distance from the tangent ﬁeld, respec-
tively. Distance from the tangent ﬁeld (labeled as “D”)Figure 1 Example of measuring the distance from tangent ﬁeld
(LADmax). The LAD artery is shown in green and the edges of the tan
LAD is 1.14 cm and the LADmax is 2.96 Gy.was used as the predictor of LADmax. A logistic sigmoid
curve was used to model the training data to develop an
equation to predict LADmax from D. In this procedure,
the outcome LADmax was transformed and regression
models were developed for the transformed LADmax as a
function of a polynomial of D; the model (transformed
from logistic sigmoid curve model) with the largest R2
was selected; this model was then back transformed to the
logistic sigmoid curve form. In addition, the other recor-
ded measurements (listed previously) were considered for
inclusion in these models and the contributions were
evaluated by examining the additional increments to the
R2 value. Cross-validation methods were used to test the
stability of this logistic sigmoid curve model on the
training data. In an n-fold cross-validation procedure, we
equally divided the training data into n subsets and ﬁt the
logistic sigmoid curve model on n-1 subsets, leaving 1
subset of data as the “testing set” to obtain the tested
ﬁtting error. By regarding each of the n subsets (n Z 10,
15, 20) as the “testing set,” we obtained the average ﬁtting
error by using n-fold cross-validation. From this logistic
sigmoid curve model, we identify the cut-point for D such
that the LADmax is <10 Gy; 95% conﬁdence intervals
(CIs) are provided for both the cut-point and the corre-
sponding LADmax. As a supportive analysis, we also ﬁt
the model for patients with D greater than the identiﬁededge to left anterior descending (LAD) artery dose maximum
gent ﬁelds are shown in yellow. The distance from ﬁeld edge to
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error for the training data with D greater than the cut-
point, and for the validation cohort.
Results
Table 1 provides a summary of the characteristics for
the 146 patients included in the training set. Figure 2
provides the scatter plots and the correlation coefﬁcients
between LADmax and distance from cavity to LAD,
cavity size, breast separation, ﬁeld size AP-direction LPO
ﬁeld, and distance from the tangent ﬁeld, respectively, for
these 146 patients. From these scatter plots, we observe
the lack of any direct relationships of LADmax with
distance from the tumor cavity to LAD, cavity size, breast
separation, and ﬁeld size AP-direction LPO ﬁeld. We note
the low linear correlations between the LADmax and
distance from tumor cavity to LAD (0.47), cavity size
(0.18), breast separation (0.02), and ﬁeld size AP-
direction LPO ﬁeld (0.28). However, the linear corre-
lation between LADmax and distance from the tangent
ﬁeld indicates that these 2 variables are highly inversely
correlated (0.84). Moreover, we observe a reverse sig-
moid shape relationship between LADmax and distance
from the tangent ﬁeld.
Next, we transformed LADmax to LADmax-trans
as follows: logit(LADmax/5000) where logit(x) Z
x/(1x), and performed linear regressions of LADmax-
trans on polynomial terms of D. By selecting the
largest R2 (0.95) from these linear regressions and
back-transforming LADmax-trans to LADmax, we
obtained the following equation to ﬁt this sigmoid shape
relationship (Fig 3):LAD maxZ5000 exp
 0:52 3:76Dþ 0:77D2 þ 0:95D3 0:44D4 þ 0:05D5
1þ expð  0:52 3:76Dþ 0:77D2 þ 0:95D3 0:44D4 þ 0:05D5Þ ð1ÞAdditional parameters were added to this model
with only minimal change in R2 to 0.951 that indicated
the model with D alone provides a parsimoniousTable 1 Training data: summary statistics for all measurements (n
Variable Mean
Distance from tumor cavity to LAD (cm) 2.47
Cavity size (mL) 101.94
Breast separation (cm) 15.76
Field size anteroposterior-direction left posterior
oblique ﬁeld (cm)
13.52
Distance from the tangent ﬁeld (cm) 0.21
LADmax (Gy) 17.90
LADmean (Gy) 4.95
LAD, left anterior descending artery; LADmax, left anterior descending arteryprediction model. The square root of mean square
error for the training data was 2.41 Gy. Based on the
large range of the outcome LADmax (maximum, 49.2
Gy), this error was relatively small (<5%). We also
performed cross-validations to test the model ﬁt. The
average square root of mean square error was 2.82
Gy for 10-fold cross-validation; 2.61 Gy for 15-fold
cross-validation; and 2.47 Gy for 20-fold cross-
validation. The largest average error of 2.82 Gy was
5.8% of the largest LADmax and 15% of the mean of
the LADmax, which indicate adequate ﬁt for the model
(Eq 1). From the model (Eq 1), for D greater than
cut-point 2.46 mm (95% CI, 2.19-2.74 mm), then
LADmax was less than 10 Gy (95% CI, 9.30-10.72 Gy).
Thus, to obtain LADmax <10 Gy, in practice, the
distance from the tangent ﬁeld edge to the LAD should
be >2.46 mm.
To predict LADmax from D (>2.46 mm), we reﬁt
the training data only for patients with D >2.46 mm
(63 of 146 patients) and found the following relationship:
LAD maxZ122:8þ 166:1=D ð2Þ
The square root of mean square error was 0.66
Gy (7% of the max of LADmax, 16% of the mean of
LADmax) on the training data (63 of 146 patients) and
0.50 Gy (4% of the max of LADmax, 14% of the mean of
LADmax) on the testing data (53 patients). Figures 4
and 5 show the ﬁt for the original data and the test data,
respectively.
Test the association between LADmean, a commonly
reported parameter, and distance, we collected LADmean
dose on the initial 146 patients in the training set
(eFigure A; available as supplementary material onlineonly at www.practicalradonc.org). Based on our data, the
LADmean was maintained at <3.3 Gy when the ﬁeld
edge was kept >2.46 mm.Z 146)
SD Median Range
2.00 1.78 0.01, 10.83
87.52 69.40 11.24, 398.40
2.95 15.45 9.45, 26.34
3.41 13.15 5.80, 25.00
0.68 0.13 1.53, 3.11
14.35 14.32 1.72, 49.20
4.62 3.10 0.90, 25.50
dose maximum; LADmean, left anterior descending artery dose mean.


























































































Figure 2 Scatter plots of left anterior descending (LAD) artery dose maximum (LADmax) versus distance from boost cavity to LAD,
cavity size, breast separation, ﬁeld size anteroposterior (AP)-direction left posterior oblique (LPO) ﬁeld, and distance from the tangent
ﬁeld (training data).
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This study aimed to develop a clinical planning tool to
provide a “rule of thumb” for the radiation oncologist
when designing the tangent ﬁelds by providing a LAD-
max/LAD mean dose estimate before dosimetric plan
optimization. This allows the physician to make minor
adjustments to gantry angle and primary collimation to
have a signiﬁcant impact on the dose delivered to the
LAD. This tool also permits a physician to perform a
rapid mental cost-beneﬁt analysis between target coverage
and LADmax/LADmean before the treatment plan is
calculated. Although the distance between the LAD and
the tangent ﬁeld edge is modiﬁable by the clinician, other
factors inherent to the individual patient may also inﬂu-
ence the maximum dose to the LAD. We identiﬁed some
of the patient-speciﬁc factors that could be predictive of
LADmax/LADmean as the size of the tumor cavity for the
radiation boost, the distance from the tumor cavity to thetangent ﬁeld edge, the breast separation, and the AP
dimension of the tangent ﬁeld: all of these parameters
were found to have a low negative correlation with
LADmax. In the series analyzed, the LADmax was
consistently kept <10 Gy when the posterior edge of the
tangents ﬁelds was situated >2.46 mm from the LADmax
point, regardless of boost cavity size, boost cavity loca-
tion, ﬁeld size, or patient breast separation. Moreover, no
patients had a LADmean >3.3 Gy when the edge of the
tangent ﬁeld was >2.46 mm.
Inter- and intraobserver variability in the contouring of
the LAD could skew the interpretation of dosimetric and
clinical results. We tried to limit variability by using a
cardiac atlas to guide LAD organs-at-risk contouring14
and adopted a consistent method of measuring the dis-
tance from the tangent ﬁeld edge to the LADmax. All
women analyzed in this study were treated in the prone
treatment position; a patient set-up that has been shown to
reduce radiation dose to the heart and lungs,15,16 and to
Figure 3 Left anterior descending artery dose maximum (LADmax) model for training data (n Z 146).
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positioning is becoming more widely available with
nearly one-third of centers polled having this technology
in their armamentarium in a recent survey.17 Furthermore,Figure 4 Left anterior descending artery dose maximum (LADmax)
mm (n Z 53).the number of centers adopting this technique will likely
increase with recent publication of randomized data
demonstrating improved cosmesis in large-breasted
women treated in the prone compared with the supinemodel ﬁt for training data with distance from tangent ﬁeld >2.46
Figure 5 Left anterior descending artery dose maximum (LADmax) model ﬁt for validation cohort (n Z 53).
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the beneﬁt of prone technique to decrease coronary artery
dose,19 we routinely treat the majority of women at our
institution prone because of the demonstrable beneﬁt in
both cardiac volume exposed to radiation15 and LAD
dose.20 The different results reported by other in-
vestigators likely reﬂect the use of prone techniques
that interpose a wedge under the contralateral breast,
forcing an axial rotation that enhances the displacement of
the heart toward the chest wall when prone.21 This
displacement can be avoided by assuring that the patient’s
sternum is on the prone breast board and the head is
turned toward the treated breast; both measures result in
maintaining the body on a horizontal plane parallel to
ground.22
Other techniques, such as deep inspiratory breath
hold,19-21 respiratory gating,22 and proton therapy23
have also been used to decrease the dose to the heart
and lungs because even low doses of irradiation have
been found to correlate with an increase in cardiovas-
cular disease.24 Deep inspiratory breath hold has the
beneﬁt of maintaining patients in the supine position,
often more comfortable for elderly or otherwise inﬁrm
patients, but it requires highly trained staff and a
cooperative patient. Respiratory gating removes the
stress component associated with breath hold but it
signiﬁcantly extends treatment duration.25 Because of
their characteristic dose distribution, protons are a
promising approach to assure cardiac sparing in breast
cancer patients and an ongoing national prospective
randomized trial is comparing proton versus photonradiation technique in women with nonmetastatic breast
cancer (NCT02603341).
Controversy exists about which speciﬁc cardiac dosi-
metric parameter best correlates with patient outcomes.
Darby et al adopted the mean dose to the entire heart as
the most predictive measure of major coronary events.6 In
contrast, other investigators consider LAD dose more
relevant, with debate over whether the mean or maximum
dose is most predictive. Investigators at Duke University
studied single photon emission tomography myocardial
perfusion imaging in 69 patients who had undergone ra-
diation for left-sided breast cancer and found perfusion
defects in the LAD distribution, indicating a likely
mechanism of cardiac damage.26 The dose parameter used
in this study was percent of the left ventricle receiving
>50% of the prescription dose with no reporting of
speciﬁc LAD dose parameters. In a Swedish series of 199
patients, LAD stenosis measured by angiography was
more common in left-sided than right-sided breast cancer
patients who had undergone radiation therapy as part of
their management.27 Interestingly, Aznar et al found that
in 7 of 24 evaluated patients undergoing radiation for left-
sided breast cancer, the volume of heart irradiated was
within predeﬁned dose constraints, but a high dose was
still delivered to the LAD.28 Alternatively, in 1 patient in
this study, the LAD dose was low, but the V20 Gy was
elevated at 19%. This paradoxical effect warrants accurate
contouring and dose monitoring of the LAD in addition to
classic volumetric heart constraints. Despite this evidence,
no published dose constraint for the LAD exists, either for
LADmean or LADmax.
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the total prescribed dose) based on preclinical data from
using a single dose of 10 Gy.11 This threshold is arbitrary
because it reﬂects the lack of robust human data corre-
lating LAD dose with outcomes. In addition, preexisting
individual risk is likely to determine late morbidity of
heart radiation therapy; even minimal artery exposure
could accelerate atherosclerosis in the genetically sus-
ceptible individual. We have modeled this concept and
found that the effect of radiation exposure on the risk of
future cardiac disease appears to be multiplicative, with
the highest absolute radiation exposure risks corre-
sponding to the highest baseline cardiac risk.29
We found that placing the tangent ﬁelds at a minimum
distance of 2.46 mm from the closest point of the con-
toured LAD limits the LADmax to 10 Gy and LADmean
to 3.3 Gy. Because our patients were planned and treated
prone, a prospective validation in left breast cancer
patients treated supine should be conducted and include
an assessment of intrafraction movement of the chest
wall. Respiration movements during the delivery of
treatment supine likely modify the distance of LAD from
the ﬁeld.
Another limitation of this study is the unconventional
dose and fractionation scheme used, but radiobiological
modeling conﬁrmed by long term clinical data30-33 have
demonstrated equivalence to the standard fractionation of
46 to 50 Gy to the breast with a sequential boost of 14 or
10 Gy to the tumor cavity, over a total of 6 weeks. Ra-
diation Therapy Oncology Group 1005 is comparing
accelerated radiation with a concomitant boost versus
standard fractionation with a sequential boost. The dose
and fractionation in the accelerated treatment arm are
comparable to those of the regimen used in this report. In
any event, the model presented (Eq 1) can easily be
applied to any dose and fractionation.
In conclusion, we believe the simple tool presented
could be of use in the daily challenge of converging safety
and efﬁciency to ensure the best protection from long-
term cardiovascular effects in irradiated left breast cancer
patients.Supplementary Data
Supplementary material for this article (http://dx.doi.
org/10.1016/j.prro.2016.08.001) can be found at www.
practicalradonc.org.References
1. Bergonie JT, Tribondeau L. De quelques resultats de la radio-
therapie et essai de ﬁxation d’une technique rationnelle. CR Séances
Acad Sci. 1906;143:983-985.
2. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of
differences in the extent of surgery for early breast cancer on localrecurrence and 15-year survival: An overview of the randomised
trials. Lancet. 2005;366:2087-2106.
3. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following
treatment of Hodgkin’s disease in children and adolescents. J Clin
Oncol. 1993;11:1208-1215.
4. Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease
after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol
Phys. 2005;61:842-850.
5. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from
heart disease and lung cancer after radiotherapy for early breast
cancer: Prospective cohort study of about 300,000 women in US
SEER cancer registries. Lancet Oncol. 2005;6:557-565.
6. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart dis-
ease in women after radiotherapy for breast cancer. N Engl J Med.
2013;368:987-998.
7. Sardaro A, Petruzzelli MF, D’Errico MP, Grimaldi L, Pili G,
Portaluri M. Radiation-induced cardiac damage in early left breast
cancer patients: Risk factors, biological mechanisms, radiobiology,
and dosimetric constraints. Radiother Oncol. 2012;103:133-142.
8. Correa CR, Das IJ, Litt HI, et al. Association between tangential
beam treatment parameters and cardiac abnormalities after deﬁnitive
radiation treatment for left-sided breast cancer. Int J Radiat Oncol
Biol Phys. 2008;72:508-516.
9. Jagsi R, Grifﬁth KA, Koelling T, Roberts R, Pierce LJ. Rates of
myocardial infarction and coronary artery disease and risk factors in
patients treated with radiation therapy for early-stage breast cancer.
Cancer. 2007;109:650-657.
10. Chung E, Corbett JR, Moran JM, et al. Is there a dose-response
relationship for heart disease with low-dose radiation therapy? Int
J Radiat Oncol Biol Phys. 2013;85:959-964.
11. Baker JE, Fish BL, Su J, et al. 10 Gy total body irradiation increases
risk of coronary sclerosis, degeneration of heart structure and
function in a rat model. Int J Radiat Biol. 2009;85:1089-1100.
12. Jozsef G, DeWyngaert JK, Becker SJ, Lymberis S, Formenti SC.
Prospective study of cone-beam computed tomography image-
guided radiotherapy for prone accelerated partial breast irradiation.
Int J Radiat Oncol Biol Phys. 2011;81:568-574.
13. Mitchell J, Formenti SC, DeWyngaert JK. Interfraction and intra-
fraction setup variability for prone breast radiation therapy. Int J
Radiat Oncol Biol Phys. 2010;76:1571-1577.
14. Feng M, Moran JM, Koelling T, et al. Development and validation
of a heart atlas to study cardiac exposure to radiation following
treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:
10-18.
15. Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs
supine positioning for breast cancer radiotherapy. JAMA. 2012;308:
861-863.
16. Lymberis SC, de Wyngaert JK, Parhar P, et al. Prospective assess-
ment of optimal individual position (prone versus supine) for breast
radiotherapy: Volumetric and dosimetric correlations in 100 pa-
tients. Int J Radiat Oncol Biol Phys. 2012;84:902-909.
17. Dundas KL, Pogson EM, Barumalai V, et al. Australian survey on
current practices for breast radiotherapy. J Med Imaging Radiat
Oncol. 2015;59:736-742.
18. Veldeman L, Schiettecatte K, De Sutter C, et al. The 2-year cosmetic
outcome of a randomized trial comparing prone and supine whole-
breast irradiation in large-breasted women. Int J Radiat Oncol Biol
Phys. 2016;95:1210-1217.
19. Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to
reduce irradiated heart volume in breast cancer patients. Int J Radiat
Oncol Biol Phys. 2001;49:199-204.
20. Register S, Takita C, Reis I, Zhao W, Amestoy W, Wright J. Deep
inspiration breath-hold technique for left-sided breast cancer: An
analysis of predictors for organ-at-risk sparing. Med Dosim. 2015;
40:89-95.
21. Zellars R, Bravo PE, Tryggestad E, et al. SPECT analysis of cardiac
perfusion changes after whole-breast/chest wall radiation therapy
Advances in Radiation Oncology: OctobereDecember 2016 LAD maximum dose prediction 381with or without active breathing coordinator: Results of a ran-
domized phase 3 trial. Int J Radiat Oncol Biol Phys. 2014;88:778-
785.
22. Giraud P, Djadi-Prat J, Morelle M, et al. Contribution of respiratory
gating techniques for optimization of breast cancer radiotherapy.
Cancer Invest. 2012;30:323-330.
23. Lin LL, Vennarini S, Dimofte A, et al. Proton beam versus photon
beam dose to the heart and left anterior descending artery for left-
sided breast cancer. Acta Oncol. 2015;54:1-8.
24. Little MP, Azizova TV, Bazyka D, et al. Systematic review and
meta-analysis of circulatory disease from exposure to low-level
ionizing radiation and estimates of potential population mortality
risks. Environ Health Perspect. 2012;120:1503-1511.
25. Cui G, Housley DJ, Chen F, Mehta VK, Shepard DM. Delivery
efﬁciency of an Elekta linac under gated operation. J Appl Clin Med
Phys. 2014;15:4713.
26. Lind PA, Pagnanelli R, Marks LB, et al. Myocardial perfusion
changes in patients irradiated for left-sided breast cancer and
correlation with coronary artery distribution. Int J Radiat Oncol Biol
Phys. 2003;55:914-920.
27. Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary
artery stenosis after radiation for breast cancer. J Clin Oncol. 2012;
30:380-386.28. Aznar MC, Korreman SS, Pedersen AN, Persson GF, Josipovic M,
Specht L. Evaluation of dose to cardiac structures during breast
irradiation. Br J Radiol. 2011;84:743-774.
29. Brenner DJ, Shuryak I, Jozsef G, Dewyngaert KJ, Formenti SC.
Risk and risk reduction of major coronary events associated with
contemporary breast radiotherapy. JAMA Intern Med. 2014;174:
158-160.
30. Bentzen SM, Shuryak I, Jozsef G, Dewyngaert KJ, Formenti SC.
The UK Standardisation of Breast Radiotherapy (START) Trial A of
radiotherapy hypofractionation for treatment of early breast cancer:
A randomised trial. Lancet Oncol. 2008;9:331-341.
31. Osa EO, DeWyngaert K, Roses D, et al. Prone breast intensity
modulated radiation therapy: 5-year results. Int J Radiat Oncol Biol
Phys. 2014;89:899-906.
32. Cooper BT, Formenti-Ujlaki GF, Li X, et al. Prospective random-
ized trial of prone accelerated intensity modulated breast radiation
therapy with a daily versus weekly boost to the tumor bed. Int J
Radiat Oncol Biol Phys. 2016;95:571-578.
33. Finkel MA, Cooper BT, Li X, Fenton-Kerimian M, Goldberg JD,
Formenti SC. Quality of life in women undergoing breast irradi-
ation in a randomized, controlled clinical trial evaluating different
tumor bed boost fractionations. Int J Radiat Oncol Biol Phys.
2016;95:579-589.
